Pricelists.org Pricelists.org Se connecter S'inscrire

Psychedelic Harm Reduction

☆☆☆☆☆ (0 reviews)
Show price history
Psychedelic Harm Reduction
Lowest price (incl. delivery)
24 334,00 JPY
Typical price1 513,72 PLN
Lowest (90 days)59,70 PLN
Offers4
Last updatedil y a 1 semaine
See best offer
Price history (90 days)
Full history
2026-08-08 2026-08-15
Historique des prix
Mis à jour lePrix
2026-08-0859,70
2026-08-15201,00
Vendeur Product price Delivery Total Disponibilité Updated
SP SpringerNatureLink Shop INT 24 309,00 JPY 25,00 JPY 24 334,00 JPY Disponible il y a 5 jours View offer
SP Springer Nature Author 24 309,00 JPY 29,00 JPY 24 338,00 JPY Disponible il y a 1 semaine View offer
VI VitalSource 181,89 EUR 29,00 EUR 210,89 EUR Disponible il y a 1 semaine View offer
SP SpringerNatureLink Shop INT 201,00 EUR 15,00 EUR 216,00 EUR Disponible il y a 5 jours View offer

Les prix et la disponibilité peuvent changer. Dernière mise à jour: 08.08.2026 22:48.

EAN 9783032211064
Springer Nature
0,0
☆☆☆☆☆
0 reviews
5★ 0%
4★ 0%
3★ 0%
2★ 0%
1★ 0%

Product reviews

Rating
No reviews yet — be the first!
Classic psychedelics such as psilocybin, LSD, ayahuasca, 5-MeO-DMT, and mescaline are multifaceted substances that have been used for healing and ritual purposes for millennia. In recent years, scientific interest in their therapeutic potential has resurged, yielding promising results for the treatment of mental health conditions, including depression, anxiety, and substance use disorders. At the same time, growing public interest and enthusiastic media coverage have contributed to increasing use in non-clinical contexts. Although psychedelics are considered not addictive and exhibit very low toxicity, their use can, in some cases, be associated with considerable risks and complications. To date, these risks remain underresearched, and many mental health professionals are insufficiently informed about their pathophysiology, differential diagnosis and clinical management. This book seeks to address this gap. From an interdisciplinary perspective, it aims to contribute to a more nuanced and balanced understanding of the benefit–risk ratio and to offer practical guidance for managing complications that may arise when psychedelics are used in therapy and beyond. The chapter "Classifying Psychedelic-Related Complications" is available open access under the Creative Commons Attribution Non Commercial - No Derivatives 4.0 International License via link.springer.com.

Similar products